Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malte Lenders

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Drugs|March 15, 2021
Fabry Disease: The Current Treatment LandscapeMalte Lenders, Eva Brand
Gut Microbes|January 29, 2022
Fabry disease - a multisystemic disease with gastrointestinal manifestationsMalte Lenders, Eva Brand
Innere Medizin (Heidelberg, Germany)|August 6, 2024
[What is confirmed in the treatment of Fabry's disease?]Malte Lenders, Eva Brand
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 21, 2021
Precision medicine in Fabry diseaseMalte Lenders, Eva Brand
Frontiers in Immunology|December 26, 2022
Assessment and impact of dose escalation on anti-drug antibodies in Fabry diseaseMalte Lenders, Eva Brand
Molecular Genetics and Metabolism|December 28, 2019
FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patientsMalte Lenders, Eva Brand
Drugs|November 8, 2021
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry DiseaseMalte Lenders, Eva Brand
Ebiomedicine|April 29, 2025
Impact of ER stress and the unfolded protein response on Fabry diseaseMalte Lenders, Elisa Rudolph, Eva Brand
Molecular Therapy. Methods & Clinical Development|September 30, 2020
<i>In Vitro</i> and <i>In Vivo</i> Amenability to Migalastat in Fabry DiseaseMalte Lenders, Franciska Stappers, Eva Brand
Nephron|March 20, 2025
Lysosomal Storage-Independent Fabry Disease Variants with α-Galactosidase A Misprocessing-Induced ER Stress and the Unfolded Protein ResponseMartina Živná, Malte Lenders, Stanislav Kmoch
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Drugs|March 15, 2021
Fabry Disease: The Current Treatment LandscapeMalte Lenders, Eva Brand
Gut Microbes|January 29, 2022
Fabry disease - a multisystemic disease with gastrointestinal manifestationsMalte Lenders, Eva Brand
Innere Medizin (Heidelberg, Germany)|August 6, 2024
[What is confirmed in the treatment of Fabry's disease?]Malte Lenders, Eva Brand
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 21, 2021
Precision medicine in Fabry diseaseMalte Lenders, Eva Brand
Frontiers in Immunology|December 26, 2022
Assessment and impact of dose escalation on anti-drug antibodies in Fabry diseaseMalte Lenders, Eva Brand
Molecular Genetics and Metabolism|December 28, 2019
FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patientsMalte Lenders, Eva Brand
Drugs|November 8, 2021
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry DiseaseMalte Lenders, Eva Brand
Ebiomedicine|April 29, 2025
Impact of ER stress and the unfolded protein response on Fabry diseaseMalte Lenders, Elisa Rudolph, Eva Brand
Molecular Therapy. Methods & Clinical Development|September 30, 2020
<i>In Vitro</i> and <i>In Vivo</i> Amenability to Migalastat in Fabry DiseaseMalte Lenders, Franciska Stappers, Eva Brand
Nephron|March 20, 2025
Lysosomal Storage-Independent Fabry Disease Variants with α-Galactosidase A Misprocessing-Induced ER Stress and the Unfolded Protein ResponseMartina Živná, Malte Lenders, Stanislav Kmoch
Pageof 7